Founded in Berkeley, United States, XOMA Corporation is a biotechnology royalty aggregator with a core mission to improve human health. The company focuses on acquiring economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates. By providing non-dilutive and non-recourse funding, XOMA enables biotech companies to advance their internal drug candidates without financial strain. Their expansive portfolio of licenses underscores their commitment to fostering innovation in the biotech sector.

XOMA's notable affiliated individuals include its experienced management team and board members with deep expertise in biotechnology and finance. The company has attracted significant investment from leading venture capital firms and institutional investors. Key achievements include the successful acquisition of numerous high-potential royalty interests, which have positioned XOMA as a pivotal player in the biotech industry. Their impact is evident in the accelerated development of promising drug candidates, ultimately contributing to advancements in medical treatments and patient care.